We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Frontage Laboratories and Frontage Clinical Services have unveiled plans to provide full service human radiolabeled Absorption, Metabolism, and Excretion (hAME) study capabilities, subject to receipt of required regulatory approvals.
Frontage Holdings Corporation, a contract research organization (CRO) providing integrated, science-driven research, analytical and development services with presence in both North America and China.